Rafael Holdings, Inc. holds interests in clinical and early stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. The company operates in two segments, Pharmaceuticals and Real Estate. It engages in the leasing of a commercial office building, as well as an associated 800-car public garage; and development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company's lead drug candidate is CPI-613 (devimistat), which is being evaluated in various clinical studies, including two Phase III registrational clinical trials for the treatment of metastatic pancreatic cancer and r/r acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.
P/B ratio for Rafael Holdings, Inc. (RFL)
P/B ratio as of 2024: 0.43
According to Rafael Holdings, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.43. At the end of 2023 the company had a P/B ratio of 0.46.
P/B ratio history for Rafael Holdings, Inc. from 2015 to 2024
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2024 | 0.43 |
| 2023 | 0.46 |
| 2022 | 0.38 |
| 2021 | 6.84 |
| 2020 | 1.89 |
| 2019 | 2.48 |
| 2018 | 1.06 |
| 2017 | 3.04 |
| 2016 | 3.27 |
| 2015 | 0.00 |